BNZ-1 not checked

Equillium

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Main trialPhase 2
“This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly for 3 months to adults diagnosed with moderate to severe alopecia areata, defined as having a \>50% loss of terminal hair on the scalp. The study has three periods: * 30-Day Screening Period * 3-Month Treatment Period * 3-Month Follow-up Period The study will be conducted at approximately 15-20 clinical sites in the United States.”In the company’s words, NCT03532958 on ClinicalTrials.gov

Other drugs for Alopecia Areata

All 16 drugs for Alopecia Areata

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Withdrawn Nov 2022 Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BNZ-1

Following is part of Solo: you see every change to BNZ-1 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in